MK-0518B (EU Sourced Lamivudine) Bioequivalence Study

Trial Profile

MK-0518B (EU Sourced Lamivudine) Bioequivalence Study

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2015

At a glance

  • Drugs Lamivudine/raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top